Mice with heterozygous deletion of Scn1a are a model of Dravet syndrome, an infant-onset epileptic encephalopathy most often caused by mutation of SCN1A. Scn1a+/- mice recapitulate many of the features of Dravet syndrome, including spontaneous seizures and premature lethality (Miller et al., 2014; Ogiwara et al., 2007; Yu et al., 2006). In order to determine the effect of PRAX-562 on spontaneous seizures and survival, F1.Scn1a+/- Dravet mice will be treated with PRAX-562compounded in chow or vehicle control chow. Feeding test article compounded in chow minimizes stressful manipulations that may provoke seizures in Scn1a+/- mice and adversely influence outcomes. In our experience, formulation of test article in chow is more reliable and efficient than administration in drinking water.
|Effective start/end date||10/1/21 → 9/30/22|
- Praxis Precision Medicines, Inc. (Kearney AGMT 10/12/21)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.